Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Avalon Pharmaceuticals has initiated a phase I clinical trial of its investigational compound AVN944 in cancer patients with advanced hematological malignancies.
Subscribe to our email newsletter
The phase I clinical trial is designed as an open-label, repeat dose-escalation study for the evaluation of the safety and tolerability of AVN944 in adult patients with advanced hematological malignancies including those with leukemia, lymphoma or myeloma.
The study is designed to determine the optimal dose with which to advance phase II efficacy trials
“We believe that AVN944 has the potential to offer oncologists and cancer patients improved options in several types of cancers where other therapies fail,” said Dr Kenneth Carter president and CEO of Avalon.
AVN944 was in-licensed by Avalon from Vertex Pharmaceuticals in February of 2005. Vertex conducted a phase I trial in the UK in normal human volunteers where AVN944 was shown to be orally bioavailable and well-tolerated.